Skip to content
Search

Latest Stories

STADA appoints Nigel Stephenson to lead UK business

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023.

Based in Huddersfield, UK, Stephenson will report directly to STADA’s Head of Western Europe and Germany, Stephan Eder.


He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA’s Mid-Sized European Markets.|

A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies.

He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland.

“With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership,” stated Eder.

“Building on the strong progress made under Rudolf Bär over the past year, I am confident that Nigel will lead our team in the UK to deliver strong, sustainable growth.”

Stephenson started his career as part of the IBM Global Leaders Program in the US. He then worked for more than 9 years at Procter & Gamble, spanning local and regional marketing roles for key brands such as Ariel, before subsequently taking over cross-regional and global marketing responsibilities.

He continued his personal growth at two renowned global healthcare companies, Novartis and GSK, developing from leading regional and global marketing roles in Switzerland and Poland to general management positions for Romania & Moldova and Switzerland. In his last position as General Manager Switzerland at Haleon, Nigel successfully demonstrated exceptional leadership skills and achieved significant growth for the organization.

“I am looking forward to further strengthening the STADA growth mindset in UK, working on iconic brands such as Covonia, Care, Cetraben, Hedrin, Oilatum and Zoflora, as well as our growing Generics and Specialty portfolios in the UK,” Stephenson commented.

“Based on the strong commercial performance, product launches and employee engagement achieved under Rudolf’s leadership, I am sure that our high-performance team will continue to deliver sustainable growth and to outperform the industry.”

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less